This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Lymphoma Treatment Market Size, Trends & Analysis - Forecasts to 2026 By Drug (Keytruda, Revlimid, Adcetris, Rituxan/MabThera, Imbruvica, Opdivo, Others) By Type (Non-Hodgkin Lymphoma and Hodgkin Lymphoma), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis, and Competitor Analysis
The medical term Lymphoma alludes to that particular sort of disease that attacks the lymphatic system of the human body. Lymphoma severely influences the lymphocytes consequently prompting unusual and fast duplication and development of the cells of the immune system. Lymphocytes allude to the cells of human beings’ immune systems.
Some of the leading factors of the market are the rising geriatric populace, expanding mindfulness among the majority concerning the accessible diagnostic advancements and treatment choices for lymphoma. Different mechanical progressions, including the advancement of innovative immune checkpoint inhibitors, which block proteins from mixing and increment in the reaction strength of T-cells against cancer cells, are adding to the market development. Moreover, extensive development and research (R&D) exercises in the field of oncology, alongside wholesome improvement in the medical infra, are expected to drive the market further. Besides, the prerequisite for pretreatment alternatives to administer progressed therapeutics in patients for the treatment of lymphoma will empower the sound development of the market within a reasonable time frame. Also, the demand for improved and better clinical results for patients will set out business opportunities for the lymphoma treatment market during the predicted time frame.
Huge pharmaceutical organizations working in the oncology space are adopting techniques, for example, coordinated efforts and acquisitions to additionally fortify their situation in the lymphoma treatments market. In the previous year, cancer therapeutics saw a considerable number of coordinated efforts, reflecting players developing inspired by this area. Various research institutions and associations worldwide are teaming up to create novel treatments for the treatment of lymphoma.
Additionally, the introduction of a few novel treatments and label augmentation of popularized items are anticipated to help the development. For instance, in 2018, the U.S. FDA approved Adcetris that is used in patients with advanced Hodgkin lymphoma in combination with chemotherapy. In 2015, Amgen, Inc. worked together with Merck and Co., Inc. to help a cancer immunotherapy stage 1b/3 examination, exploring Keytruda in blend with Blincyto in people with Diffuse Large B-cell Lymphoma (DLBCL), which is the most widely recognized kind of NHL. This examination is a multicentre, open-mark, randomized preliminary to assess viability and wellbeing in patients with DLBCL.
Based on the drug, the market can be segmented into Keytruda, Revlimid, Adcetris, Rituxan/MabThera, Imbruvica, Opdivo, and Others. Revlimid held the largest share of the market and is relied upon to observe huge development during the predicted time frame. Revlimid sales are being driven by an expansion in the period of treatment of cancer. Rituxan/MabThera held the second-largest market share attributable to the expanding utilization of this item in numerous different indications alongside a high precipitation rate in significant business sectors.
Based on the type, the market can be segregated into Non-Hodgkin Lymphoma and Hodgkin Lymphoma. NHL held the biggest offer attributable to the presence of blockbuster medications like Revlimid, Rituxan, and Imbruvica, which are probably the greatest income-creating oncology drugs.
Hodgkin lymphoma is relied upon to observe the quickest development during the estimated time frame because of the label expansion of existing medications and the introduction of new treatments for relapsed or refractory HL. Additionally, the presence of a solid item pipeline alongside the presumed commercialization of these items is one of the variables expected to drive development.
As per the geographical analysis, the market of Lymphoma Treatment can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central South America. North America held the largest share and is anticipated to lead during the predicted time frame. This can be ascribed to the presence of major players, accessibility of novel medications, small settled medical infrastructure, and high R&D expenses.
Asia Pacific is relied upon to observe the quickest development during the estimated time frame with a significant CAGR attributable to an ascent in medical care consumption, high neglected clinical necessities, expansion in mindfulness about therapy alternatives, and accessibility of successful therapy in arising nations like China and South Korea.
Abbott Laboratories, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Ltd., Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., and Seattle Genetics, Inc. are the top players in the Lymphoma Treatment market.
Please note: This is not an exhaustive list of companies profiled in the report.
In March 2020, the US Food and Drug Administration unveiled a partial clinical hold on the phase 1 trial of ACTR707, a pipeline candidate for lymphoma treatment.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Global Lymphoma Treatment Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Drugs Overview
2.1.3 Type Overview
2.1.5 Regional Overview
Chapter 3 Global Lymphoma Treatment Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Rising cases of lymphomas to fuel demand
3.3.1.2 Increasing expenditure in healthcare sector by government
3.3.2 Industry Challenges
3.3.2.1 High cost due to certain therapeutics
3.4 Prospective Growth Scenario
3.4.1 Drugs Growth Scenario
3.4.2 Type Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Lymphoma Treatment Market, By Drugs
4.1 Drugs Outlook
4.2 Keytruda
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Revlimid
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Adcetris
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
4.5 Rituxan/MabThera
4.5.1 Market Size, By Region, 2019-2026 (USD Million)
4.6 Imbruvica
4.6.1 Market Size, By Region, 2019-2026 (USD Million)
4.7 Opdivo
4.7.1 Market Size, By Region, 2019-2026 (USD Million)
4.8 Others
4.8.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Global Lymphoma Treatment Market, By Type
5.1 Type Outlook
5.2 Non-Hodgkin Lymphoma
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Hodgkin Lymphoma
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Global Lymphoma Treatment Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Drugs, 2019-2026 (USD Million)
6.2.3 Market Size, By Type, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.3 Market Size, By Type, 2019-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Type, 2019-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.3.9.2 Market Size, By Type, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Drugs, 2019-2026 (USD Million)
6.4.3 Market Size, By Type, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.4.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Type, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.4.7.2 Market size, By Type, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Type, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Drugs, 2019-2026 (USD Million)
6.5.3 Market Size, By Type, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Type, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Drugs, 2019-2026 (USD Million)
6.6.3 Market Size, By Type, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Type, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Type, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Drugs, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Type, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Abbott Laboratories
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Bristol-Myers Squibb Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Takeda Pharmaceutical Company Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 Celgene Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Eli Lilly and Company
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Merck & Co., Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 Johnson & Johnson
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Seattle Genetics, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Other Companies
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
The Global Lymphoma Treatment Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Lymphoma Treatment Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
